Starling Oncology anticipates $650M-$670M 2026 revenue while adding 310,000 capitated lives and refinancing debt to 2031 (NASDAQ:STLN)
· seekingalpha.com
Starling Oncology (STLN) Q2 2026 earnings call: profitability, refinancing to 2031, capitation contract wins and raised guidance.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...